94 related articles for article (PubMed ID: 23789962)
1. Effect of rosiglitazone on liver structure and function in genetically diabetic Akita mice.
Hemmeryckx B; Gaekens M; Gallacher DJ; Lu HR; Lijnen HR
Basic Clin Pharmacol Toxicol; 2013 Nov; 113(5):353-60. PubMed ID: 23789962
[TBL] [Abstract][Full Text] [Related]
2. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice.
García-Ruiz I; Rodríguez-Juan C; Díaz-Sanjuán T; Martínez MA; Muñoz-Yagüe T; Solís-Herruzo JA
Hepatology; 2007 Aug; 46(2):414-23. PubMed ID: 17654601
[TBL] [Abstract][Full Text] [Related]
3. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
4. Combined effects of rosiglitazone and conjugated linoleic acid on adiposity, insulin sensitivity, and hepatic steatosis in high-fat-fed mice.
Liu LF; Purushotham A; Wendel AA; Belury MA
Am J Physiol Gastrointest Liver Physiol; 2007 Jun; 292(6):G1671-82. PubMed ID: 17322064
[TBL] [Abstract][Full Text] [Related]
5. Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice?
Hemmeryckx B; Hoylaerts MF; Gallacher DJ; Rong Lu H; Himmelreich U; D'hooge J; Swinnen M; Lijnen HR
Eur J Pharmacol; 2013 Jan; 700(1-3):23-31. PubMed ID: 23228931
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of gypenosides against fatty liver disease induced by high fat and cholesterol diet and alcohol in rats.
Qin R; Zhang J; Li C; Zhang X; Xiong A; Huang F; Yin Z; Li K; Qin W; Chen M; Zhang S; Liang L; Zhang H; Nie H; Ye W
Arch Pharm Res; 2012 Jul; 35(7):1241-50. PubMed ID: 22864747
[TBL] [Abstract][Full Text] [Related]
7. Dietary β-conglycinin prevents fatty liver induced by a high-fat diet by a decrease in peroxisome proliferator-activated receptor γ2 protein.
Yamazaki T; Kishimoto K; Miura S; Ezaki O
J Nutr Biochem; 2012 Feb; 23(2):123-32. PubMed ID: 21447441
[TBL] [Abstract][Full Text] [Related]
8. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
Hong XZ; Li LD; Wu LM
Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
[TBL] [Abstract][Full Text] [Related]
9. Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Bedoucha M; Atzpodien E; Boelsterli UA
J Hepatol; 2001 Jul; 35(1):17-23. PubMed ID: 11495036
[TBL] [Abstract][Full Text] [Related]
10. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D attenuates high fat diet-induced hepatic steatosis in rats by modulating lipid metabolism.
Yin Y; Yu Z; Xia M; Luo X; Lu X; Ling W
Eur J Clin Invest; 2012 Nov; 42(11):1189-96. PubMed ID: 22958216
[TBL] [Abstract][Full Text] [Related]
13. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
14. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
15. Ethanolic extract of seabuckthorn (Hippophae rhamnoides L) prevents high-fat diet-induced obesity in mice through down-regulation of adipogenic and lipogenic gene expression.
Pichiah PB; Moon HJ; Park JE; Moon YJ; Cha YS
Nutr Res; 2012 Nov; 32(11):856-64. PubMed ID: 23176796
[TBL] [Abstract][Full Text] [Related]
16. Roles of adipose restriction and metabolic factors in progression of steatosis to steatohepatitis in obese, diabetic mice.
Larter CZ; Yeh MM; Van Rooyen DM; Teoh NC; Brooling J; Hou JY; Williams J; Clyne M; Nolan CJ; Farrell GC
J Gastroenterol Hepatol; 2009 Oct; 24(10):1658-68. PubMed ID: 19788606
[TBL] [Abstract][Full Text] [Related]
17. Dual Outcomes of Rosiglitazone Treatment on Fatty Liver.
Gao M; Ma Y; Alsaggar M; Liu D
AAPS J; 2016 Jul; 18(4):1023-31. PubMed ID: 27125895
[TBL] [Abstract][Full Text] [Related]
18. PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.
Oishi K; Tomita T; Itoh N; Ohkura N
Thromb Res; 2011 Nov; 128(5):e81-5. PubMed ID: 21757225
[TBL] [Abstract][Full Text] [Related]
19. [Peroxisome proliferator activated receptor gamma activation and overexpression prevent hepatocellular apoptosis of nutritional fibrotic steatohepatitis in mice].
Nan YM; Han F; Kong LB; Li Y; Wang RQ; Zhao SX
Zhonghua Gan Zang Bing Za Zhi; 2011 Jul; 19(7):521-6. PubMed ID: 22152244
[TBL] [Abstract][Full Text] [Related]
20. A high-fat diet and multiple administration of carbon tetrachloride induces liver injury and pathological features associated with non-alcoholic steatohepatitis in mice.
Kubota N; Kado S; Kano M; Masuoka N; Nagata Y; Kobayashi T; Miyazaki K; Ishikawa F
Clin Exp Pharmacol Physiol; 2013 Jul; 40(7):422-30. PubMed ID: 23611112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
